Human Genome Sciences Inc. reported net sales of $7.8 million for lupus drug Benlysta (belimumab) in the second quarter, the drug's first full quarter on the market since gaining FDA approval in March. (See BioWorld Today, March 11, 2011.)
With the market for initial public offerings (IPO) refusing to heat up as many had hoped, biotech companies are once again turning to reverse mergers for entry to the public markets.
With a weak market for initial public offerings (IPO) and Nasdaq cracking down on reverse mergers, Coronado Biosciences Inc. found an alternate route to a public listing: filing a Form-10.
NeoStem Inc. – which has its hands in a variety of cell therapy businesses including early stage research, storage, manufacturing and overseas treatment – is acquiring privately held stem cell firm Amorcyte Inc.
Who's afraid of the big, bad initial public offering (IPO) market? Apparently not cancer firm Merrimack Pharmaceuticals Inc., which filed late Friday to raise up to $172.5 million in an IPO. Apparently not J.P. Morgan, either. The investment bank is listed on Merrimack's book as well as on the book for Clovis Oncology Inc., which last month filed to raise up to $149.5 million in an IPO. (See BioWorld Today, June 24, 2011.)
We just finished running the numbers for biotech fundraising in the first half of 2011, and . . . drum roll please . . . the numbers are good! Well, they’re good if you’re a publicly traded, pre-commercial biotech, anyway. Overall, biotech companies raised a total of $13.3 billion in the first half of 2011, up a whopping 64 percent over the $8.1 billion raised in the first half of 2010, according to data from BioWorld Insight and BioWorld Snapshots. That breaks down into three categories: $2.1 billion raised by private biotechs, $4.6 billion raised in initial and follow-on public...
Biotech companies raised a total of $13.3 billion in the first half of 2011, reclaiming much of the fundraising ground that was lost when the markets crashed in 2008.
Biotech companies raised a total of $13.3 billion in the first half of 2011, up a whopping 64 percent over the $8.1 billion raised in the first half of 2010, according to data from BioWorld Insight and BioWorld Snapshots.
